Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab + Relatlimab vs Nivolumab for Resectable High-Risk Basal Cell Carcinoma
NCT06624475Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in basal cell carcinoma (BCC), sponsored by University of California, San Diego. Started Aug 2025; status: recruiting.
02
Drugs
relatlimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06624475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624475.